There is, in fact, nothing natural or evolutionary about the pharmaceutical giants’ lurch toward small laboratories outside the company. It also isn’t simply a fresh ruse aimed at higher profitability and generating greater shareholder value. Instead, this move reflects a widespread and deep cultural angst about discovery in medical science, going back 50 years, which has combined with an increasing sensitivity to risk-taking. The results are not pretty.
Monday, February 21, 2011
Big Pharma, small ambition | spiked
Subscribe to:
Post Comments (Atom)
1 comment:
Post a Comment